Published On: Sat, Sep 17th, 2016

ProQR Therapeutics NV (PRQR) Upgraded to “Hold” by Zacks Investment Research

ProQR Therapeutics NV (NASDAQ:PRQR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Saturday.
According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
A number of other equities research analysts have also weighed in on PRQR. Chardan Capital started coverage on shares of ProQR Therapeutics NV in a report on Monday, June 20th. They issued a “neutral” rating and a $4.50 price objective for the company. Leerink Swann restated a “buy” rating on shares of ProQR Therapeutics NV in a report on Thursday, August 18th. Finally, JMP Securities restated a “buy” rating on shares of ProQR Therapeutics NV in a report on Tuesday, September 6th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $15.94.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

ProQR Therapeutics NV (NASDAQ:PRQR) opened at 5.48 on Friday. ProQR Therapeutics NV has a 12 month low of $3.48 and a 12 month high of $20.05. The firm has a 50-day moving average of $5.45 and a 200 day moving average of $5.05. The firm’s market capitalization is $127.94 million.
ProQR Therapeutics NV (NASDAQ:PRQR) last announced its quarterly earnings data on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.00. Equities research analysts forecast that ProQR Therapeutics NV will post ($2.14) earnings per share for the current year.
A hedge fund recently raised its stake in ProQR Therapeutics NV stock. Sabby Management LLC boosted its position in shares of ProQR Therapeutics NV (NASDAQ:PRQR) by 276.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,934 shares of the biopharmaceutical company’s stock after buying an additional 110,063 shares during the period. Sabby Management LLC owned approximately 0.64% of ProQR Therapeutics NV worth $732,000 at the end of the most recent quarter. 39.21% of the stock is owned by hedge funds and other institutional investors.
About ProQR Therapeutics NV
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Receive News & Ratings for ProQR Therapeutics NV Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ProQR Therapeutics NV and related companies with’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>